{"prompt": "['Product: MK-3475', '138', 'Protocol/Amendment No.: 604-09', 'trial flow chart. If delayed, present consent at next possible Subject Visit. Consent', 'forms signed by the subject will be kept at the clinical trial site under secure storage', 'for regulatory reasons.', \"A template of each trial site's approved informed consent will be stored in the\", \"Sponsor's clinical document repository.\", 'c. eCRF Documentation for Future Biomedical Research Specimens', 'Documentation of subject consent for Future Biomedical Research will be captured in', 'the electronic Case Report Forms (eCRFs). Any specimens for which such an', 'informed consent cannot be verified will be destroyed.', 'd. Future Biomedical Research Specimen(s)', 'Collection of specimens for Future Biomedical Research will be performed as', 'outlined in the trial flow chart. In general, if additional blood specimens are being', 'collected for Future Biomedical Research, these will usually be obtained at a time', 'when the subject is having blood drawn for other trial purposes.', '4. Confidential Subject Information for Future Biomedical Research', 'In order to optimize the research that can be conducted with Future Biomedical Research', \"specimens, it is critical to link subject' clinical information with future test results. In fact\", 'little or no research can be conducted without connecting the clinical trial data to the', 'specimen. The clinical data allow specific analyses to be conducted. Knowing subject', 'characteristics like gender, age, medical history and treatment outcomes are critical to', 'understanding clinical context of analytical results.', 'To maintain privacy of information collected from specimens obtained for Future', 'Biomedical Research, the Sponsor has developed secure policies and procedures. All', 'specimens will be single-coded per ICH E15 guidelines as described below.', 'At the clinical trial site, unique codes will be placed on the Future Biomedical Research', 'specimens. This code is a random number which does not contain any personally', 'identifying information embedded within it. The link (or key) between subject identifiers', 'and this unique code will be held at the trial site. No personal identifiers will appear on', 'the specimen tube.', '5. Biorepository Specimen Usage', 'Specimens obtained for the Sponsor will be used for analyses using good scientific', 'practices. Analyses utilizing the Future Biomedical Research specimens may be', 'performed by the Sponsor, or an additional third party (e.g., a university investigator)', 'designated by the Sponsor. The investigator conducting the analysis will follow the', \"Sponsor's privacy and confidentiality requirements. Any contracted third party analyses\", 'will conform to the specific scope of analysis outlined in this sub-trial. Future Biomedical', 'Research specimens remaining with the third party after specific analysis is performed', 'will be reported to the Sponsor.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '139', 'Protocol/Amendment No.: 604-09', '6. Withdrawal From Future Biomedical Research', 'Subjects may withdraw their consent for Future Biomedical Research and ask that their', 'biospecimens not be used for Future Biomedical Research. Subjects may withdraw', 'consent at any time by contacting the principal investigator for the main trial. If medical', 'records for the main trial are still available, the investigator will contact the Sponsor', 'using the designated mailbox (clinical.specimen.management@merck.com)', \"Subsequently, the subject's specimens will be flagged in the biorepository and restricted\", 'to main study use only. If specimens were collected from study participants specifically', 'for Future Biomedical Research, these specimens will be removed from the biorepository', 'and destroyed. Documentation will be sent to the investigator confirming withdrawal', 'and/or destruction, if applicable. It is the responsibility of the investigator to inform the', 'subject of completion of the withdrawal and/or destruction, if applicable. Any analyses', 'in progress at the time of request for withdrawal/destruction or already performed prior to', 'the request being received by the Sponsor will continue to be used as part of the overall', 'research trial data and results. No new analyses would be generated after the request is', 'received.', 'In the event that the medical records for the main trial are no longer available (e.g., if the', 'investigator is no longer required by regulatory authorities to retain the main trial', 'records) or the specimens have been completely anonymized, there will no longer be a', \"link between the subject's personal information and their specimens. In this situation, the\", 'request for withdrawal of consent and/or destruction cannot be processed.', '7. Retention of Specimens', 'Future Biomedical Research specimens will be stored in the biorepository for potential', 'analysis for up to 20 years from the end of the main study. Specimens may be stored for', 'longer if a regulatory or governmental authority has active questions that are being', 'answered. In this special circumstance, specimens will be stored until these questions', 'have been adequately addressed.', 'Specimens from the trial site will be shipped to a central laboratory and then shipped to', 'the Sponsor-designated biorepository. If a central laboratory is not utilized in a particular', 'trial, the trial site will ship directly to the Sponsor-designated biorepository. The', 'specimens will be stored under strict supervision in a limited access facility which', 'operates to assure the integrity of the specimens. Specimens will be destroyed according', 'to Sponsor policies and procedures and this destruction will be documented in the', 'biorepository database.', '8. Data Security', 'Databases containing specimen information and test results are accessible only to the', 'authorized Sponsor representatives and the designated trial administrator research', 'personnel and/or collaborators. Database user authentication is highly secure, and is', 'accomplished using network security policies and practices based on international', 'standards to protect against unauthorized access.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}